



15 June 2017

## **ASX ANNOUNCEMENT**

### **Penthrox Regulatory Dossier accepted for review in Canada**

Medical Developments International Limited (ASX: MVP) is delighted to announce that the regulatory dossier for Penthrox® submitted in Canada has now been accepted for review by the Canadian regulatory body, Health Canada.

Accepting the MVP dossier for review, triggers a milestone payment of CAD\$0.25 million from MVP's partner, Purdue Pharma (Canada).

MVP Chief Executive Officer, Mr. John Sharman said: "This is another positive step towards globalizing Penthrox."

#### Enquiries:

John Sharman  
Chief Executive Officer  
+61 (3) 9547 1888

David Williams  
Chairman  
+61 (0) 414 383 593



#### **About Pentrox**

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

#### **About Medical Developments International Ltd**

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

#### **About Purdue Pharma Canada L.P**

Purdue Pharma Canada is a research-based pharmaceutical company with its headquarters, R&D operations, and manufacturing located in Pickering, Ontario. The company is a leader in the research and development of medicines for the treatment of pain and central nervous system disorders (ADHD) with a growing pipeline of prescription and over the counter products. Privately held, Purdue Pharma Canada is independently associated with the worldwide Purdue/Napp/Mundipharma network of companies.